D-Index & Metrics Best Publications
Pierre P. Massion

Pierre P. Massion

Vanderbilt University Medical Center
United States

Research.com Recognitions

Awards & Achievements

2015 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

His main research concerns Lung cancer, Cancer research, Pathology, Cancer and Lung. His research integrates issues of Carcinogenesis and Cohort in his study of Lung cancer. His Cancer research study incorporates themes from Mutation, Gene mutation, Signal transduction, Exon and Rovalpituzumab tesirine.

His Pathology study integrates concerns from other disciplines, such as Biomarker, Proteomics and Adenocarcinoma. His Cancer research incorporates elements of Survival rate, Carcinoma, Immunology and Hazard ratio. His Lung research is multidisciplinary, incorporating elements of Frozen section procedure and Receiver operating characteristic.

His most cited work include:

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers (1094 citations)
  • Comprehensive genomic profiles of small cell lung cancer (866 citations)
  • The national lung screening trial: Overview and study design (715 citations)

What are the main themes of his work throughout his whole career to date?

Pierre P. Massion mostly deals with Lung cancer, Cancer research, Internal medicine, Cancer and Pathology. His research in Lung cancer intersects with topics in Biomarker, Radiology, Lung and Early detection. His research integrates issues of Non small cell, Small Cell Lung Carcinoma, Cell growth, Metastasis and Adenocarcinoma in his study of Cancer research.

Pierre P. Massion has included themes like Gastroenterology, Endocrinology and Oncology in his Internal medicine study. His research investigates the connection with Cancer and areas like Immunology which intersect with concerns in COPD. His research in Pathology tackles topics such as Proteomics which are related to areas like Bioinformatics.

He most often published in these fields:

  • Lung cancer (76.56%)
  • Cancer research (30.99%)
  • Internal medicine (27.60%)

What were the highlights of his more recent work (between 2018-2021)?

  • Lung cancer (76.56%)
  • Cancer research (30.99%)
  • Lung (25.26%)

In recent papers he was focusing on the following fields of study:

Lung cancer, Cancer research, Lung, Internal medicine and Lung cancer screening are his primary areas of study. His work carried out in the field of Lung cancer brings together such families of science as Retrospective cohort study, Emergency medicine, Confidence interval, Radiology and Tumor progression. The concepts of his Cancer research study are interwoven with issues in Cell growth, Autoantibody, Small hairpin RNA, Non small cell and Adenocarcinoma.

In his research on the topic of Lung, Computed tomographic, Prostate, Noninvasive biomarkers and Diagnostic biomarker is strongly related with Nodule. His Internal medicine study combines topics in areas such as Gastroenterology and Oncology. Pierre P. Massion studied Cohort and Cancer that intersect with CD8.

Between 2018 and 2021, his most popular works were:

  • Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. (169 citations)
  • Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges (77 citations)
  • The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution (65 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

His scientific interests lie mostly in Lung cancer, Lung, Internal medicine, Cancer research and Lung cancer screening. His Lung cancer study incorporates themes from Retrospective cohort study, Confidence interval, Tumor progression, Qualitative feedback and Receiver operating characteristic. His Lung research is multidisciplinary, incorporating perspectives in Normal results, Curative treatment and Emergency medicine.

Pierre P. Massion works mostly in the field of Internal medicine, limiting it down to topics relating to Oncology and, in certain cases, Human genetics and Non invasive. His Cancer research research includes elements of Cell growth, NEUROD1, ASCL1, Small hairpin RNA and Genetically Engineered Mouse. The various areas that Pierre P. Massion examines in his Lung cancer screening study include Odds ratio, Guideline and Family medicine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama.
Journal of Clinical Oncology (2012)

1723 Citations

Comprehensive genomic profiles of small cell lung cancer

Julie George;Jing Shan Lim;Se Jin Jang;Yupeng Cun.
Nature (2015)

1489 Citations

The national lung screening trial: Overview and study design

Constantine A. Gatsonis;Denise R. Aberle;Christine D. Berg;William C. Black.
Radiology (2011)

1111 Citations

Proteomic patterns of tumour subsets in non-small-cell lung cancer.

Kiyoshi Yanagisawa;Yu Shyr;Baogang J Xu;Pierre P Massion.
The Lancet (2003)

786 Citations

Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer

Joseph Amann;Shailaja Kalyankrishna;Pierre P. Massion;Joyce E. Ohm.
Cancer Research (2005)

517 Citations

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Charles M. Rudin;John T. Poirier;Lauren Averett Byers;Caroline Dive.
Nature Reviews Cancer (2019)

481 Citations

Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.

Nicholas J. Wang;Zachary Sanborn;Kelly L. Arnett;Laura J. Bayston.
Proceedings of the National Academy of Sciences of the United States of America (2011)

456 Citations

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

Laura R. Saunders;Alexander J. Bankovich;Wade C. Anderson;Monette A. Aujay.
Science Translational Medicine (2015)

438 Citations

Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study

Fumiko Taguchi;Benjamin Solomon;Vanesa Gregorc;Heinrich Roder.
Journal of the National Cancer Institute (2007)

432 Citations

Significance of p63 amplification and overexpression in lung cancer development and prognosis.

Pierre P. Massion;Peter M. Taflan;S. M. Jamshedur Rahman;Pinar Yildiz.
Cancer Research (2003)

400 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Pierre P. Massion

Richard M. Caprioli

Richard M. Caprioli

Vanderbilt University

Publications: 83

Ignacio I. Wistuba

Ignacio I. Wistuba

The University of Texas MD Anderson Cancer Center

Publications: 82

John D. Minna

John D. Minna

The University of Texas Southwestern Medical Center

Publications: 71

Charles M. Rudin

Charles M. Rudin

Memorial Sloan Kettering Cancer Center

Publications: 71

Ming-Sound Tsao

Ming-Sound Tsao

Princess Margaret Cancer Centre

Publications: 61

Pasi A. Jänne

Pasi A. Jänne

Harvard University

Publications: 48

Matthew Meyerson

Matthew Meyerson

Harvard University

Publications: 43

Adi F. Gazdar

Adi F. Gazdar

The University of Texas Southwestern Medical Center

Publications: 42

David P. Carbone

David P. Carbone

The Ohio State University

Publications: 41

Fred R. Hirsch

Fred R. Hirsch

Mount Sinai Hospital

Publications: 41

Roman K. Thomas

Roman K. Thomas

University of Cologne

Publications: 39

Anil K. Sood

Anil K. Sood

The University of Texas MD Anderson Cancer Center

Publications: 38

Paul A. Bunn

Paul A. Bunn

University of Colorado Boulder

Publications: 38

William Pao

William Pao

Roche (United States)

Publications: 38

Alice T. Shaw

Alice T. Shaw

Harvard University

Publications: 37

John V. Heymach

John V. Heymach

The University of Texas MD Anderson Cancer Center

Publications: 37

Trending Scientists

Daniel M. Dias

Daniel M. Dias

IBM (United States)

Stephen S. Intille

Stephen S. Intille

Northeastern University

Asif Ekbal

Asif Ekbal

Indian Institute of Technology Patna

Stéphane Quideau

Stéphane Quideau

Centre national de la recherche scientifique, CNRS

George R. Rossman

George R. Rossman

California Institute of Technology

Chain-Shu Hsu

Chain-Shu Hsu

National Yang Ming Chiao Tung University

Douglas H. Lowndes

Douglas H. Lowndes

Oak Ridge National Laboratory

Jan Wijnholds

Jan Wijnholds

Leiden University Medical Center

Scot R. Kimball

Scot R. Kimball

Pennsylvania State University

Youlong Xia

Youlong Xia

M-Systems

Nicola Palomero-Gallagher

Nicola Palomero-Gallagher

Forschungszentrum Jülich

Alfred W. Kaszniak

Alfred W. Kaszniak

University of Arizona

John C. Bell

John C. Bell

University of Ottawa

William von Hippel

William von Hippel

University of Queensland

William M. Mendenhall

William M. Mendenhall

University of Florida

Barry D. Kahan

Barry D. Kahan

The University of Texas at Austin

Something went wrong. Please try again later.